Amazon joins Fred Hutch on clinical trial for personalized cancer vaccine — report
Amazon is partnering with the Fred Hutchinson Cancer Research Center on a Phase I trial for a cancer vaccine targeting metastatic melanoma and breast cancer.
The clinical trial is part of Amazon’s Grand Challenge, a secretive lab the tech giant started in 2014 to work on cancer research among a number of other efforts, and was first reported in Business Insider. According to clinicaltrials.gov, the Phase I trial will test a tumor antigen vaccine therapy alongside nivolumab (Opdivo) in patients with metastatic and refractory late stage melanoma and HR+/HER2- breast cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.